Free Cash Flow

Techtronic Industries reports record profits driven by its MILWAUKEE and RYOBI brands, even as it navigates tariffs and restructures its struggling floorcare unit.

Once a failing firm, Aurelion Inc. bet its future on tokenized gold. The gamble paid off with a profitable quarter, but regulatory risks loom large.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

The digital asset giant is delisting from Toronto to streamline costs, a move that reshapes its buyback plan and how Canadian investors trade its stock.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

A major renewal with a 30M-client bank highlights the industry's shift to biometrics, boosting BIO-key's finances and solidifying its market niche.

Post-listing, the Swiss HealthTech firm pushes for US market expansion and European reimbursement, streamlining its focus on AI-powered brain health.

Hong Kong's Ming Shing Group replaces its CFO and CAO, bringing in a new financial architect as its stock tumbles and it navigates a risky Bitcoin bet.

EcoVadis awards highlight a major shift: sustainability is no longer about compliance, but a core driver of performance, resilience, and long-term value.

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.

Ag Growth International brings back its 23-year former CFO to the board, signaling a major push for operational excellence amid financial pressures.

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

With a $6B M&A war chest and a new AI focus, Roper Technologies takes the stage at Morgan Stanley. Here’s what investors will be watching for.

SaaS growth expert Eric Shoemaker takes the helm at Keebo, aiming to scale its AI-powered platform amid soaring enterprise demand for cloud cost control.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Manhattan's top landlord promotes Harrison Sitomer from intern to President, signaling a focus on stability as it navigates a complex office market.

As Mike Eastwood retires, new CFO Gary Bischoping, a tech and finance veteran, is set to guide the company's ambitious AI transformation and next chapter of growth.

The healthcare firm reports a 56% revenue surge to $3.2B, but a "material weakness" in financial controls and a delayed SEC filing cast a shadow.